ATAI Life Sciences (ATAI) Price & Analysis

Compare

1,925 Followers

ATAI Stock Chart & Stats

$4.33

-$0.11(-6.29%)

At close: Jan 08 4:00 PM EST

$4.33

-$0.11(-6.29%)

Day’s Range― - ―

52-Week Range$1.15 - $6.75

Previous CloseN/A

Volume1.44M

Average Volume (3M)4.28M

Market Cap

$1.59B

Enterprise Value$1.04B

Total Cash (Recent Filing)$114.61M

Total Debt (Recent Filing)$2.96M

Price to Earnings (P/E)―

Beta1.24

Next Earnings

Mar 26, 2026

EPS Estimate

-0.11

Last Dividend Ex-Date

Aug 27, 2018

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.28

Shares Outstanding363,214,600

10 Day Avg. Volume2,694,411

30 Day Avg. Volume4,276,352

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)1.83

Price to Sales (P/S)691.60

P/FCF Ratio-2.58

Enterprise Value/Market Cap0.65

Enterprise Value/Revenue344.47

Enterprise Value/Gross Profit-132.94

Enterprise Value/Ebitda-7.17

Forecast

1Y Price Target

$12.71

Price Target Upside193.53% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical AdvancementsNew data show improved results in treatment-resistant depression with a two-dose induction, providing compelling evidence for a multidose regimen.

Financial StabilityA recent raise means AtaiBeckley is well capitalized with a cash runway into 2029, which includes top-line data from a Phase 3 trial for BPL-003.

Regulatory ProgressBreakthrough Therapy Designation for BPL-003 in treatment-resistant depression underscores strong momentum and reinforces its leadership in the field.

Bears Say

Regulatory RisksRisks include clinical development risk tied to lead programs, competitor risk in relevant therapeutic areas, and government regulatory risk, such as the need to reschedule psychedelics.

Safety ConcernsOne serious adverse event of suicidal ideation was reported, highlighting a potential risk factor in the treatment.

ATAI Life Sciences News

Psychedelic: Atai Beckley granted U.S. patent for EMP-01

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on...

23h ago

ATAI

CMND

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Twenty One Capital, Inc....

1d ago

MRK

NAK

Atai Beckley granted U.S. patent for EMP-01

Atai Beckley (ATAI) announced that the United States Patent and Trademark Office has granted a new patent covering...

1d ago

ATAI

Psychedelic: Atai Beckley, Cybin report quarterly earnings

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on...

29d ago

PBM

ABBV

ATAI Life Sciences Files Prospectus for Share Registration

ATAI Life Sciences ( ($ATAI) ) has provided an announcement. On December 5, 2025, Atai Beckley N.V. filed...

7d ago

ATAI

AtaiBeckley: Strong Buy Rating Backed by Promising Clinical Data and Robust Financial Position

Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on ATAI Life Sciences. The associated price...

23d ago

ATAI

ATAI Life Sciences’ BPL-003 Gains Momentum with Breakthrough Therapy Designation and Strategic Merger, Reinforcing Buy Rating

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on ATAI Life Sciences today and set a price...

29d ago

ATAI

ATAI Life Sciences: Promising Clinical Developments and Strong Financial Position Drive Buy Rating

TD Cowen analyst Ritu Baral has maintained their bullish stance on ATAI stock, giving a Buy rating yesterday....

29d ago

ATAI

AtaiBeckley Advances Mental Health Therapies with FDA Milestone

Atai Life Sciences N.V. ( ($ATAI) ) has released its Q3 earnings. Here is a breakdown of the...

29d ago

ATAI

Atai Beckley reports Q3 EPS (28c), consensus (12c)

Reports Q3 revenue $749,000, consensus $55,560. “This has been a transformational quarter, highlighted by the establishment of AtaiBeckley,...

1M ago

ATAI

Atai Beckley sees cash runway into 2029

As of September 30, 2025, the Company had cash, cash equivalents and short-term securities of $114.6 million compared...

1M ago

ATAI

ATAI Life Sciences’ BPL-003 Shows Promising Phase 2b Results, Earning Buy Rating

Ami Fadia, an analyst from Needham, maintained the Buy rating on ATAI Life Sciences. The associated price target...

1M ago

ATAI

GH Research price target lowered to $35 from $40 at H.C. Wainwright

H.C. Wainwright analyst Patrick Trucchio lowered the firm’s price target on GH Research (GHRS) to $35 from $40...

1M ago

ABBV

ATAI

Buy Rating Affirmed on Promising Clinical Data and Strategic Developments for AtaiBeckley

Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on ATAI Life Sciences and keeping the price...

1M ago

ATAI

ATAI FAQ

What was ATAI Life Sciences’s price range in the past 12 months?

ATAI Life Sciences lowest stock price was $1.15 and its highest was $6.75 in the past 12 months.

What is ATAI Life Sciences’s market cap?

ATAI Life Sciences’s market cap is $1.59B.

When is ATAI Life Sciences’s upcoming earnings report date?

ATAI Life Sciences’s upcoming earnings report date is Mar 26, 2026 which is in 104 days.

How were ATAI Life Sciences’s earnings last quarter?

ATAI Life Sciences released its earnings results on Nov 12, 2025. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of -$0.115 by -$0.165.

Is ATAI Life Sciences overvalued?

According to Wall Street analysts ATAI Life Sciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does ATAI Life Sciences pay dividends?

ATAI Life Sciences pays a Notavailable dividend of $6 which represents an annual dividend yield of N/A. See more information on ATAI Life Sciences dividends here

What is ATAI Life Sciences’s EPS estimate?

ATAI Life Sciences’s EPS estimate is -0.11.

How many shares outstanding does ATAI Life Sciences have?

ATAI Life Sciences has 363,214,600 shares outstanding.

What happened to ATAI Life Sciences’s price movement after its last earnings report?

ATAI Life Sciences reported an EPS of -$0.28 in its last earnings report, missing expectations of -$0.115. Following the earnings report the stock price went down -2.257%.

Which hedge fund is a major shareholder of ATAI Life Sciences?

Currently, no hedge funds are holding shares in ATAI

ATAI Life Sciences Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

21.42%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

ATAI Life Sciences

ATAI Life Sciences is a biotechnology company focused on the development of innovative treatments for mental health disorders. Operating in the life sciences sector, ATAI aims to transform the mental health landscape by leveraging advanced therapeutics and psychedelic compounds. The company collaborates with various entities to create a diverse pipeline of products, including novel therapies for conditions such as depression, anxiety, and addiction.

ATAI Life Sciences (ATAI) Earnings & Revenues

Historic Earnings Reports

ATAI Stock 12 Month Forecast

Average Price Target

$12.71

▲(193.53% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","17":"$17","4.25":"$4.25","8.5":"$8.5","12.75":"$12.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.25,8.5,12.75,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.84,4.775384615384615,5.71076923076923,6.646153846153846,7.581538461538461,8.516923076923078,9.452307692307691,10.387692307692308,11.323076923076922,12.258461538461539,13.193846153846154,14.12923076923077,15.064615384615385,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.84,4.522307692307693,5.204615384615384,5.886923076923077,6.569230769230769,7.251538461538462,7.933846153846154,8.616153846153846,9.298461538461538,9.980769230769232,10.663076923076924,11.345384615384617,12.027692307692309,{"y":12.71,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.84,4.313846153846153,4.787692307692308,5.2615384615384615,5.735384615384615,6.2092307692307696,6.683076923076923,7.156923076923077,7.63076923076923,8.104615384615386,8.57846153846154,9.052307692307693,9.526153846153846,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.69,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.33,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.55,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.72,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.49,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.71,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.17,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.59,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.2,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.84,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.84,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >